Gapping up
In reaction to earnings/guidance:
- PRPL +6.3%, HIMS +2.9%, CLVT +2%
Other news:
- DISCA +15% (AT&T's WarnerMedia and Discovery (DISCA) creating standalone company by combining operations to form new global leader in entertainment); T +4.9%,
- MNMD +8.7% (announces receipt of Type C Meeting Responses from FDA)
- APLS +8.3% (receives FDA approval for EMPAVELI)
- ACIU +4.7% (announces that the Company and its strategic partner Janssen Pharmaceuticals, have expanded the ongoing Phase 1b/2a clinical trial of the Companies' first-in-class anti-phosphorylated-Tau vaccine candidate ACI-35.030 for the treatment of Alzheimer's disease)
- AKTS +4.1% (secures WiFi 6E reference design with third SoC maker)
- LEV +4% (receives order for 260 buses from First Student)
- SEEL +3.9% (presented study of SLS-002)
- VIAC +2.9% (Soros Fund disclosed new position)
- LABP +2.6% (Landos Biopharma and LianBio announced an exclusive collaboration and license agreement for the development and commercialization of omilancor and NX-13 in Greater China)
- VIPS +2% (Soros Fund disclosed new position)
- TME +1.8% (Soros Fund disclosed new position)
- GRTX +1.7% (announces first patient dosed with GC4711 in phase 2b GRECO-2 trial in patients with pancreatic cancer)
- INCY +1.4% (announces "positive" topline results from its pivotal Phase 3 TRuE-V clinical trial program evaluating the safety and efficacy of ruxolitinib cream, an investigational, nonsteroidal, anti-inflammatory, JAK inhibitor, topical therapy, in adolescent and adult patients with vitiligo)
- KVHI +1.3% (issued a letter to shareholders in connection with the Company's upcoming annual meeting of shareholders to be held on June 17, 2021)
- NVT +1.2% (announces $300 mln share repurchase program)
- BYND +1.1% (expands partnership with Pizza Hut)
- ONDS +1% (to acquire American Robotics for approximately $70.6 mln)
- BIDU +0.9% (Soros Fund disclosed new position)
Analyst comments:
- PLCE +3.2% (upgraded to Outperform from Neutral at Wedbush)
- TCOM +2.8% (upgraded to Overweight from Equal-Weight at Morgan Stanley)
- AMWL +2.7% (upgraded to Buy from Neutral at Guggenheim)
- PAAS +1.9% (upgraded to Outperform from Sector Perform at National Bank Financial)
- TXRH +1.7% (upgraded to Buy from Hold at Deutsche Bank)
- CMI +1.5% (upgraded to Buy from Neutral at BofA Securities)